Chinese New Year in Canada

Chinese New Year 2011 Date:

This year, Chinese New Year is February 3, 2011. It is celebrated at the same time in Canada as in China.

What is the 2011 Animal Sign?

2011 will ring in the Year of the Rabbit.

Chinese New Year Celebrations in Canada:

Canada has a significant Chinese population, with major cities like Vancouver, Montreal and Toronto featuring bustling Chinatowns.

Across Canada, every January / February - although the date changes year to year - we celebrate Chinese New Year with parades (see parade photos), performances and food.

Cities in Canada will often have a Chinese community or cultural centre; check these for related events. You may also try tourism websites for events.

Chinese New Year, Vancouver, British Columbia:

Chinese New Year, Calgary, Alberta:

• The Calgary Chinese Cultural Centre offers a 3-day celebration of Chinese New Year that culminates in a gala evening that includes the Dragon and Lions Dance.

Chinese New Year, Ottawa, Ontario:

• No Shen Yun Performing Arts: 2011 World Tour is scheduled for 2011.
• Last year, the Ottawa Chamber Orchestra presented Chinese New Year Celebrations.
• Check local Chinese community centers for events.

Chinese New Year, Toronto, Ontario:

Chinese New Year, Montreal, Quebec:

Find Your Chinese Zodiac Sign and Learn More about Chinese New Year :

Source: http://gocanada.about.com/od/eventsfestivalsholid3/p/chinese_newyear.htm

justin bieber baby credit unions tower heist reviews recursion amy schumer amy schumer ascii art

Tech's biggest misfires of 2011

The past 12 months have been a boon of technological innovation, particularly in the world of mobile devices, where top companies have been waging an arms race for the top of the smartphone and tablet hills. Not everything has been smooth sailing, however -- 2011 has also been dotted by delays, false starts, security breeches and straight up technological turf outs. Check out some of the lowlights from the year that was after the break.

Continue reading Tech's biggest misfires of 2011

Tech's biggest misfires of 2011 originally appeared on Engadget on Thu, 29 Dec 2011 13:00:00 EDT. Please see our terms for use of feeds.

Permalink   |   | Email this | Comments

Source: http://feeds.engadget.com/~r/weblogsinc/engadget/~3/oAzPyhreL-s/

st. nicholas heisman finalists heisman finalists kepler 22 b kepler 22 b rosie o donnell st nicholas

Health Tip: Use Medications Safely (HealthDay)

(HealthDay News) -- If your child isn't feeling well and needs an over-the-counter medication recommended by your pediatrician, the American Academy of Family Physicians offers these safety guidelines:

• Make sure the medicine treats only your child's symptoms, nothing more.
• Make sure any caregivers know the correct timing, dosage and type of medication your child needs.
• Always read the medication's label and follow directions carefully.
• Keep medications stored in their original packaging, so you can easily refer to instructions.
• Never give cough and cold medication to a child younger than age 4 or aspirin to anyone younger than age 18.
• Don't combine medications unless your child's pediatrician says it's OK to do so.
• Don't give any adult medication to a child.

Source: http://us.rd.yahoo.com/dailynews/rss/meds/*http%3A//news.yahoo.com/s/hsn/20111223/hl_hsn/healthtipusemedicationssafely

los angeles weather big ten acc challenge scott disick kourtney kardashian kourtney kardashian lipitor lipitor

France ponders removing risky breast implants (AP)

PARIS ? Emmanuelle Maria's breasts were burning and globules of silicone gel were protruding into her armpits. Her implants had exploded inside her. Yet her doctors, she says, told her nothing was wrong.

Now, she wants the French government to tell 30,000 women to get their implants removed ? at the state's expense ? to call attention to their risks and save others from potential pain and indignity.

Prompted by calls from implant wearers and leading doctors, French health authorities are considering a drastic and unprecedented move: recommending mass surgery to rid the country of a type of breast implant that investigators say was secretly made with cheap industrial silicone whose medical dangers remain unclear.

Governments around Europe are hanging on France's decision Friday. Tens of thousands more women in Britain, Italy, Spain and other European nations are walking around with the same pre-filled implants, made by the now-defunct French company Poly Implant Prothese, or PIP.

Health officials from several European countries held a conference call Wednesday to discuss the implants, Portugal's Director-General of Health, Dr. Francisco Jorge, told The Associated Press. European Commission spokesman Frederic Vincent said no decisions were made, but France informed the others of the situation.

The main concern in France is the risk of rupture ? more than 1,000 of the 30,000 such implants in France have burst, according to the French health safety agency AFSSAPS ? and uncertainty over what risks the suspected industrial silicone gel could pose when it leaks inside the body.

Meanwhile, eight cases of cancer among women with the implants, including one who died in November, have crystallized concerns and heightened pressure on the government to take action. Friday's government decision will depend partly on guidance from the French National Cancer Institute.

The implants in question were not sold in the U.S., where concerns about silicone gel implants overall led to a 14-year ban on their use. Silicone implants were brought back to the market in 2006 after research ruled out cancer, lupus and some other concerns.

In Britain, the law firm Hugh James solicitors said it is acting for over 250 women with PIP implants who are trying to sue clinics that provided the surgery. In a statement, the firm said the news have been worrying to its clients, many of whom "have already suffered terrible problems as a result of their implants," including ruptures and leakages.

Still, British health authorities say they see no reason so far to have the French-made implants systematically removed, and have said that there is not enough evidence of a link between silicone implants and cancer. Italy's Health Ministry is holding a meeting Thursday to discuss the French-made implants.

Experts from the French Health Ministry will meet Friday to decide what to recommend for women who have the implants. The implants were taken off the market last year after French authorities discovered the company misreported the type of silicone used.

Plastic surgeon Maurice Mimoun of Paris' Saint Louis Hospital said a rupture could leak the silicone gel internally. That in turn could require surgery on other parts of the body to remove it.

"The problem is that these implants are made with a gel that we don't know," he said in an interview. "Once these implants are removed, the story is not over ... we don't know" if there might be other consequences, he said.

Mimoun has recommended that the government push for implant removals, but insisted that the operations needn't be carried out in haste.

Women have filed more than 2,000 legal complaints since the implants were recalled last year, and an investigation into officials at PIP is under way. Investigators suspect the company used cheaper industrial silicone instead of silicone meant for medical use in the implants, cutting costs by up to euro1 million ($1.3 million) a year.

The company has suspended its activities and is being liquidated. Its phones are no longer functioning and emails sent to its staff were not answered.

Implant wearer Maria described wanting new breasts to improve her self-image after an adolescence troubled by a bone disease that left her covered in scars.

She was given the PIP silicone implants in 2007, and started developing burning pains in early 2010. She consulted her surgeon and another specialist he recommended. "They told me, 'There's nothing wrong,'" she recounted.

She then went to two other doctors who confirmed that both implants had burst. She had them removed, and at her own expense, had two new ones implanted ? made by another company.

"The product is dangerous. They told us there was nothing toxic," she told The Associated Press by telephone from her office in La Seyne-sur-Mer in southern France ? the same town where PIP was based.

She accused the company and surgeons of "playing Russian roulette with the health of others."

Tina, a retired Frenchwoman who had her PIP implants removed earlier this year, didn't experience any pain when they ruptured, but said she now worries about what might have leaked into her body in the months she lived unwittingly with the burst implants.

"It's time for surgeons to admit that these implants pose special risks. What we need is a bit of humanity," she said, embarrassed by her ignorance of the dangers and frustrated that doctors didn't warn her about the PIP implants after they were recalled last year.

She didn't want her last name used because some people in her entourage do not know that she had her breasts augmented.

Recommending implant removal for all 30,000 Frenchwomen with these artificial breasts would impose substantial costs to France's state health care system and pose logistical challenges in finding enough surgeons to perform the operations.

The French health system does not pay for cosmetic breast implants, which make up the majority of breast operations, but government spokeswoman Valerie Pecresse said state health care would pay for implant removal operations "if it involves a health and public safety emergency."

It is unclear, however, whether the state would pay for replacement implants. About 40,000 women in Britain are believed to have the PIP implants as well. Britain's Medicines and Healthcare Products Regulatory Agency said its own testing had found no evidence of toxicity in the PIP implants and no evidence to suggest that women should have them removed.

But the agency said in a statement it "will consider any new evidence which comes to light as a priority."

The British Association for Plastic, Reconstructive and Aesthetic Surgeons said the expected announcement by French medical authorities was "a precautionary measure."

"Surgeons will be in contact with any patient who has received this type of implant if any action is required," it said. "If women are worried or believe that their implants may have ruptured, they should contact their implanting surgeon."

The Italian Health Ministry says it is monitoring the "possible health risks linked to the PIP implants signaled by the French authorities" and it has convened a meeting of its top level health experts for Thursday.

Portugal's General Directorate for Health estimates 1,500-2,000 Portuguese women had the implants and is advising them to visit their doctor for a checkup, Jorge said.

In Denmark, authorities says less than 100 women had these breast implants and the Danish Medicines Agency is in close contact with French authorities.

The French company used to sell saline-filled implants in the United States but its authorization was revoked after a re-evaluation by the Food and Drug Administration in 2000, mainly because of what the FDA deemed incomplete studies.

___

Lauran Neergaard in Washington, Jill Lawless and Sylvia Hui in London, Frances D'Emilio in Rome, Barry Hatton in Lisbon, Ciaran Giles in Madrid, Jan Olsen in Copenhagen contributed to this report.

Source: http://us.rd.yahoo.com/dailynews/rss/health/*http%3A//news.yahoo.com/s/ap/20111221/ap_on_he_me/eu_france_breast_implants

odom colt mccoy vt vt cleveland browns fred thompson fred thompson

To Prevent Theft: Car Seat Identifies Drivers Sitting Down

A group of researchers at the Advanced Institute of Industrial Technology in Tokyo has developed a car seat [JP, PDF] that can identify drivers when sitting down. The trick is that the system measures the pressure people apply on the seat through a set of 360 sensors. Each sensor is measuring pressure by its own and sends the information to a laptop, which aggregates the information to show key data like the highest value of pressure, area of contact on the seat (see below), and other factors. According to its makers, the system was able to identify drivers with 98% accuracy during experiments.

Source: http://feedproxy.google.com/~r/Techcrunch/~3/4QiVa-RvJzc/

grover norquist grover norquist nfl week 12 picks nfl week 12 picks jason witten ucla vs usc rich rodriguez

Total Recall: Best Joel Silver Productions

We count down the best-reviewed work of the Sherlock Holmes: A Game of Shadows producer.

This weekend, Robert Downey, Jr. and Jude Law return to theaters in Sherlock Holmes: A Game of Shadows, reuniting the duo that sleuthed up more than $520 million in worldwide box office receipts during their 2009 debut. But it isn't just Robert and Jude who deserve credit for all this blockbuster detecting -- there's a whole team behind Hollywood's latest incarnation of Holmes and Watson, including director Guy Ritchie and screenwriters Kieran and Michele Mulroney (not to mention the characters' creator, Sir Arthur Conan Doyle). But today, we're here to pay tribute to someone else: Joel Silver, a co-producer on the Holmes franchise and someone whose instinct for developing major movie hits has made him one of the industry's most sought-after talents for the last 30 years. You know his name, you've seen it on the credits of countless films, and now it's time to take a look at some of the most critically successful of the bunch. It's time for Total Recall!

---

70%

Over 100 years after he made his debut on the printed page, Sir Arthur Conan Doyle's famous detective got the big budget Joel Silver treatment in the aptly titled Sherlock Holmes, starring Robert Downey, Jr. as the intrepid sleuth and Jude Law as his faithful sidekick Watson. Joined by Rachel McAdams as the mysterious Irene Adler and assisted by Guy Ritchie's action-heavy direction, Holmes made solving 19th-century mysteries cool again -- and entertained critics such as Bill Goodykoontz of the Arizona Republic, who wrote, "Playing literature's greatest detective as a sort of self-loathing action hero, Downey has an absolute blast. And thanks to his performance in Sherlock Holmes, so do we."

---

73%

The famously cantankerous Alan Moore disavowed the Hollywood version of his graphic novel, taking issue with the way the Wachowski-produced V for Vendetta used the political subtext of the book -- which was written in the 1980s -- to frame an argument against neoconservatism. And Moore probably had a point, too -- but as hard as it is to begrudge an author his criticism of an adaptation of his work, it's also easy to understand why the gripping, stylish Vendetta was a critical and commercial hit when it reached theaters in early 2006. James McTeigue's direction is at its most thrilling here, and the Wachowskis' script manages to incorporate thought-provoking themes with good old-fashioned action. And then there was Natalie Portman, who had her head shaved on camera for her role as Evey Hammond, the ordinary citizen driven to vigilantism by a totalitarian political regime (as well as some remarkably persuasive speeches from a masked, yet still utterly charismatic, Hugo Weaving). V for Vendetta was so dark, and so unapologetically political, that it's still a little hard to believe it was a $100 million-plus hit -- but it certainly didn't hurt that it provoked eloquent praise from critics like Jonathan R. Perry of the Tyler Morning Telegraph, who wrote, "V screams loudly and long, with visceral, kinetic fury and with style to burn. It's so brazen, it's kind of brilliant."

---

74%

Four years after The Matrix earned $463 million at the box office, Silver and the Wachowskis got the band back together for The Matrix Reloaded, in which Neo (Keanu Reeves) starts getting to the bottom of the conspiracy that has enslaved humanity -- and introduces audiences to the Merovingian (Lambert Wilson) and Persephone (Monica Bellucci). Though it didn't offer quite as many paradigm-shifting thrills as the original, Reloaded outgrossed the first installment by a few hundred million -- and impressed critics like Colin Covert of the Minneapolis Star Tribune, who wrote, "For sheer exhilarating spectacle, The Matrix Reloaded is the film to beat this year."

---

76%

Like any great blockbuster producer, Silver knows how to smell a hit -- and during the 1980s, that scent was Eau de Schwarzenegger. Silver and Ahnuld teamed up twice during the decade, and the results -- Commando and Predator -- are among any action fan's favorites from the era. Here, Schwarzenegger must lead a team of tough-as-nails soldiers into the jungle on what's believed to be a rescue mission for prisoners of war -- but which quickly turns out to be a bloody fight against a dreadlocked interstellar hunter (played to perfection by the late, lamented Kevin Peter Hall). Silver's pictures from the period tended to follow a certain formula, but at this point, familiarity hadn't yet bred contempt -- and anyway, if Predator lacks a surplus of moving parts, it does what it's supposed to with cool precision. "It achieves a sort of sublime purity," sighed an appreciative Tim Brayton for Antagony & Ecstacy. "It is Action Movie, nothing more and nothing less."

---

80%

After the immense success of 1987's Lethal Weapon, and the enduring popularity of the buddy cop genre it helped define, it came as no surprise to anyone when a sequel surfaced two years later. What was shocking, however, was just how much fun Lethal Weapon 2 turned out to be. Boasting further opportunities for Gibson to test the limits of action-hero funny business as nutty LAPD sergeant Martin Riggs, some of the nastiest bad guys in any late 1980s action thriller, and rapid-fire comic relief in the form of Joe Pesci, the second Weapon flew in the face of conventional wisdom by scoring with filmgoers and critics alike. In fact, some preferred it to the original -- including scribes like Brian Orndorf, who called it "One of the finest examples of the genre, and, in my humble estimation, one of the greatest sequels put to film. Perhaps deranged hyperbole, but rarely does a follow-up outgun the original film as swiftly as Lethal 2 does."

---

84%

There's no surefire way for an actor to guarantee that any given project will be a hit at the box office, but having Joel Silver attached certainly doesn't hurt a movie's chances for success. As evidenced by most of the other entries on this list, Silver is mostly known for his commercial instincts -- which is why 2005's Kiss Kiss, Bang Bang, a skewed noir comedy directed and adapted by Shane Black (The Last Boy Scout) came as such a pleasant surprise for critics. Downey, who worked with Silver on 2003's Gothika, is squarely in his wheelhouse here, starring as a two-bit hood who repeatedly breaks the fourth wall as he stumbles from one circumstance (accidentally landing a movie role) to another (discovering a murder mystery) while trading quips with the private investigator (Val Kilmer) who's helping him research his character. Kiss Kiss saw only limited release during its brief theatrical run, but it earned high praise from the likes of the Washington Post's Desson Howe, who called it "the first movie since 1994's Pulp Fiction not just to understand movie violence as a pop cultural form... but to play it like a virtuoso violinist."

Source: http://www.rottentomatoes.com/m/1924140/news/1924140/

asu football arkansas lsu storage wars storage wars millionaire matchmaker millionaire matchmaker shawshank redemption

Insight: Stem cell therapy poised to come in from the cold (Reuters)

(Reuters) ? A rogue surgeon injects stem cells from a fetus into a sick man's brain. The cells morph and form body parts. When the man dies, the pathologist finds cartilage, skin and bone clumped in his brain.

The scene is not from a horror movie; it happened to Max Truex, a former Olympic runner who suffered from Parkinson's disease. The case sent a chill through the scientific community when it came to light 15 years ago and typifies some of the hurdles researchers have faced while trying to bring stem cell therapies to the market.

Now, it appears, their efforts are closer than ever to paying off.

Dozens of adult stem cell treatments are moving through clinical trials and showing early success, raising hopes that some could reach the market within five years.

"It will only take a few successes to really change the field," said Gil Van Bokkelen, chief executive of Athersys Inc and chairman of the Alliance for Regenerative Medicine. "As you see things getting closer and closer to that tipping point, you're going to see a frenzy of activity take place."

Many of the trials focus on heart disease and inflammatory conditions, some of the biggest markets in medicine. The cells used are derived from adult tissue such as fat, or bone marrow, thereby circumventing the ethical concerns raised by the use of cells derived from embryos.

Data for the most part remains early, but as more results emerge, pharmaceutical companies are beginning to take note.

"A lot of big companies are looking to place bets on some Phase II products once that data has been confirmed," said Paul Schmitt, managing partner at venture capital firm Novitas Capital. "Even now they're attending all the medical meetings and talking to all the stem cell companies."

Venture funds like Novitas are taking different approaches to playing the emerging field. Novitas invested $4 million in Amorcyte Inc, a company recently acquired by NeoStem Inc that is developing a treatment for heart disease. It is sticking to that investment for now.

By contrast, Aspire Capital Partners LLC is investing more broadly in the hope that one success will offset the inevitable failures.

"My philosophy in the stem cell space is that it's very difficult at this point to pick the winners and losers," said Steven Martin, managing member at Aspire. "We believe that over time there will be some very significant clinical progress, and valuations will improve, but we're still a long way from an approved therapy."

In the meantime, he said, "we are willing to be patient because we think the upside is tremendous."

GROWING INTEREST

Aastrom Biosciences Inc recently presented promising results from a mid-stage trial of its treatment for patients with critical limb ischemia, a disease in which blood flow to the extremities is restricted, at the American Heart Association's annual meeting. A mid-stage trial from Australia's Mesoblast Ltd showed its stem cell product reduced the rate of heart attacks and the need for artery clearing procedures by 78 percent.

"We're actually developing products now," said Timothy Mayleben, chief executive of Aastrom, which is using cells derived from a patient's own bone marrow to develop treatments for cardiovascular disease. "For the first time you are starting to see data being presented at major medical meetings."

Mesoblast has attracted more interest from investors than most. In late 2010, Cephalon Inc took a 20 percent stake in the company, which now has a market value of $2 billion -- far greater than any other pure play company in the space. Cephalon was bought this year by Teva Pharmaceutical Industries Ltd..

"Mesoblast gets this out-sized valuation by being a standard bearer in a risky field that everyone feels has a lot of promise," said Raghuram Selvaraju, an analyst at Morgan Joseph TriArtisan.

Shire Plc said in May it planned to establish a new regenerative medicine business, and kick-started it with the $750 million purchase of Advanced BioHealing Inc, which makes a skin substitute for treating diabetic foot ulcers.

Pfizer Inc, Johnson & Johnson and Roche Holding AG are members of the Alliance for Regenerative Medicine, a nonprofit group that promotes awareness of the field. Pfizer has a regenerative medicine unit and a partnership with Athersys. But their projects are small.

"Big pharma companies will be more interested in investing once they see data in hundreds of patients," said Schmitt.

Once that happens, there will be a land rush, he said, just as there was with monoclonal antibodies, genetically engineered molecules such as Roche's breast cancer drug Herceptin and Abbott Laboratories' rheumatoid arthritis drug Humira.

"Monoclonal antibodies were a missionary effort for many years, all through the eighties and nineties," Schmitt said. "They were called silver bullets, and eventually those bullets turned to gold."

According to GBI Research, the market for monoclonal antibodies was worth $15.6 billion in 2010 and is expected to reach $31.7 billion by 2017.

Stem cell therapy, which once promised to deliver cures for everything from Alzheimer's disease and Parkinson's to spinal cord injury, has followed a similar path of enthusiasm followed by disappointment.

"There was a lot of hype around the industry early on and the industry failed to live up to that hype," said Aastrom's Mayleben.

Now stem cell therapy is gaining credibility again as real clinical data begins to emerge.

"From an investor standpoint, the time lines are long, but the opportunity to transform medicine and science is unlike anything else out there," said Aspire's Martin.

MASTER CELLS

The promise of stem cells, which have been used for 40 years in bone marrow transplants, lies in their ability to repair tissue, reduce inflammation, regulate the immune system, and respond to calls for help from multiple places inside the body. Stem cells are the body's master cells - blank slates that renew themselves and mature into specific cell types in the heart, muscle and other organs.

Embryonic stem cells are uniquely capable of differentiating into every type of mature cell in the body, and were long viewed as the most promising for regenerating tissue.

But harvesting stem cells from embryos requires the destruction of the embryo itself, a process opposed by conservative Christian groups. Moreover, their endless capacity to divide can lead to the formation of teratomas, or stem cell cancers.

Recently, Geron Corp, the world's leading embryonic stem cell company, said it could no longer fund its stem cell work and would focus on developing cancer drugs. It closed its trial for spinal cord injury.

Unlike embryonic stem cells, adult stem cells have a more limited capacity to differentiate, but appear able to reduce inflammation and promote blood vessel formation. Furthermore, they can respond to damage in the body in a flexible and dynamic way, offering advantages over traditional drugs.

"They seem to be preprogrammed to act some way in tissue repair, not to form an organ or a tissue," said Douglas Losordo, head of stem cell research at Baxter International Inc, which is developing cell therapies for heart disease. "The cells that we use are very effective at stimulating the formation of new blood vessels, but if I wanted to make a brain cell out of those cells they would not be very good at it."

These are the type of stem cell treatments, delivered by infusion, injection or catheter, that are being developed today.

Some companies, such as Celgene Corp, Pluristem Therapeutics Inc, Athersys and Mesoblast are developing so-called allogeneic products designed to be sold with the ease and scale of a traditional pharmaceutical. Cells are taken from a single donor, expanded, frozen and shipped for use in thousands of people.

"We wanted to create a product that everyone could receive and not have to match every donor to every recipient," said Robert Hariri, chief executive of Celgene's Cellular Therapeutics unit.

Aastrom, Baxter, NeoStem and Cytori Therapeutics Inc use cells taken from a patient's own body in what is known as an autologous transfer. This personalized approach eliminates the risk that the cells will be rejected.

"There are going to be dividing lines in the industry between autologous and allogeneic and there are some indications where one will be better than the other," said Jason Kolbert, head of business development at NeoStem.

"It may be that immediately following a heart attack you would want to use an allogeneic therapy to limit the damage in those first few hours, and then follow up after day five with an autologous product like ours."

Different types of stem cell are being used for different diseases. Cytori is developing a heart disease product derived from fat cells, for example, while Celgene is using placental cells for Crohn's disease and rheumatoid arthritis therapies.

Fetal cells are also being explored. Neuralstem Inc, for example, is developing treatments for neurological disorders from an aborted fetus and is in the early stages of testing a treatment for amyotrophic lateral sclerosis, known also as Lou Gehrig's disease.

"I think Neuralstem is one to watch," said Aspire's Martin.

CHALLENGES AHEAD

As cell therapies move further through clinical trials, companies will need more money, and funding is scarce. Aastrom's shares have fallen 37 percent since reaching a year high of $3.47 in June as investors brace for another dilutive capital-raising effort.

Companies with credible partners will likely have an advantage. Athersys has a partnership with Pfizer; Cytori has a partnership with General Electric Co; Pluristem has a partnership with United Therapeutics Corp. Celgene, which makes cancer drug Revlimid, has resources of its own.

Yet even if companies remain afloat long enough to bring a product through late-stage clinical trials, it is unclear what regulators like the Food and Drug Administration will require in order to approve them.

Some believe the regulatory hurdles for treatments derived from a patient's own cells will be lower than those where the cells come from donors, since there is less risk of cell rejection. However, no clear pathway has yet been established.

"We need a clear, consistent and rigorous regulatory framework," said Athersys's Van Bokkelen "The FDA is actually willing to provide lots of guidance and assistance to sponsors, if you just ask them."

(Reporting by Toni Clarke in Boston and Deena Beasley in Los Angeles; Editing by Michele Gershberg, Edward Tobin and Tim Dobbyn)

Source: http://us.rd.yahoo.com/dailynews/rss/biotech/*http%3A//news.yahoo.com/s/nm/20111205/hl_nm/us_insight_stem_cell_therapy

ricin in god we trust ben gibbard zooey deschanel damian mcginty tj houshmandzadeh tj houshmandzadeh